Silenor is approved for use in people with chronic (long-term) or transient (short-term) insomnia characterised by difficulty with sleep maintenance.
According to Somaxon, Silenor can be used for as long as recommended by the treating physician, and is approved for use in adults and in the elderly.
Somaxon Pharmaceuticals is a specialty pharmaceutical company focused on the in-licensing, development and commercialisation of proprietary products and late-stage product candidates for the treatment of diseases and disorders in the central nervous system therapeutic area.